Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions.
We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology clinical programs.
10/20/17 4:00 p.m. ET
Minimum 15 minutes delay
- 10/13/17Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference
- 10/05/17Dermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris
- 09/14/17Dermira Announces Early Termination of the Hart-Scott-Rodino Waiting Period for License to Lebrikizumab
- 09/14/17New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
There are currently no events scheduled.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|